Mycobacterium tuberculosis Lipolytic Enzymes as Potential Biomarkers for the Diagnosis of Active Tuberculosis by Brust, Belinda et al.
Mycobacterium tuberculosis Lipolytic Enzymes as
Potential Biomarkers for the Diagnosis of Active
Tuberculosis
Belinda Brust
1,5,M e ´lanie Lecoufle
5, Edouard Tuaillon
3, Luc Dedieu





1Laboratoire de Dynamique des Interactions Membranaires Normales et Pathologiques, Universite ´s de Montpellier II et I, CNRS UMR 5235, Montpellier, France, 2INSERM,
DIMNP, Montpellier, France, 3INSERM U1058, Universite ´ de Montpellier I, De ´partement de Bacte ´riologie-Virologie, Institut de Recherche en Biothe ´rapie, Centre Hospitalier
Universitaire de Montpellier, Montpellier, France, 4CNRS UPR 9025, Universite ´ Aix-Marseille, Enzymologie Interfaciale et Physiologie de la Lipolyse, Marseille, France,
5Clinical Microbiology Division, Bio-Rad Laboratories, Steenvoorde, France
Abstract
Background: New diagnosis tests are urgently needed to address the global tuberculosis (TB) burden and to improve
control programs especially in resource-limited settings. An effective in vitro diagnostic of TB based on serological methods
would be regarded as an attractive progress because immunoassays are simple, rapid, inexpensive, and may offer the
possibility to detect cases missed by standard sputum smear microscopy. However, currently available serology tests for TB
are highly variable in sensitivity and specificity. Lipolytic enzymes have recently emerged as key factors in lipid
metabolization during dormancy and/or exit of the non-replicating growth phase, a prerequisite step of TB reactivation. The
focus of this study was to analyze and compare the potential of four Mycobacterium tuberculosis lipolytic enzymes (LipY,
Rv0183, Rv1984c and Rv3452) as new markers in the serodiagnosis of active TB.
Methods: Recombinant proteins were produced and used in optimized ELISA aimed to detect IgG and IgM serum
antibodies against the four lipolytic enzymes. The capacity of the assays to identify infection was evaluated in patients with
either active TB or latent TB and compared with two distinct control groups consisting of BCG-vaccinated blood donors and
hospitalized non-TB individuals.
Results: A robust humoral response was detected in patients with active TB whereas antibodies against lipolytic enzymes
were infrequently detected in either uninfected groups or in subjects with latent infection. High specifity levels, ranging
from 93.9% to 97.5%, were obtained for all four antigens with sensitivity values ranging from 73.4% to 90.5%, with Rv3452
displaying the highest performances. Patients with active TB usually exhibited strong IgG responses but poor IgM
responses.
Conclusion: These results clearly indicate that the lipolytic enzymes tested are strongly immunogenic allowing to
distinguish active from latent TB infections. They appear as potent biomarkers providing high sensitivity and specificity
levels for the immunodiagnosis of active TB.
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Introduction
Tuberculosis (TB) which is caused by Mycobacterium tuberculosis
(Mtb), remains one of the leading causes of death in the world [1].
Approximately one-third of world population is currently infected
with Mtb. According to the WHO, around 9.2 million new TB cases
and 1.7 million deaths occur every year [2]. The increasing global
health burden of TB is further aggravated by the alarming increase
of the number of people living with HIV and the emergence of
multi- and extensively drug-resistant Mtb strains, which requires a
longer, more costly therapeutic regimen [3,4]. One of the best
prognoses for TB comes with early diagnosis of the infection and
immediate implementation of appropriate chemotherapy. In many
countries, especially in resource constrain areas, the diagnosis of TB
largely relies on the detection of acid-fast bacilli in sputum in
conjunction with assessment of clinical symptoms and X-ray
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diagnosis performances and are time-consuming. Currently, the
tuberculin skin test based on the use of purified protein derivative
(PPD) is the only available immune-based diagnostic test for clinical
use in most developing countries. However, prior vaccination with
BCG and cross-reaction with other mycobacterial species result in a
poor specificity of this century-old test [5]. In addition, this test does
not permit to clearly distinguish between the active and latent form
of TB infection. Thus, the clinical relevance of PPD-based skin test
appears not highly reliable [6].
In recent years, important efforts have been made to develop
and rapid TB diagnosis tests. Tests based on antigens suffer from
poor sensitivity and specificity to diagnose TB cases with smear-
negative sputum samples [7,8]. Immunoassays based on the
detection of antibodies against Mtb antigens appear as an
alternative to the TB diagnosis especially in low-resource countries
[9]. In this context, numerous antigens able to trigger specific
antibody responses in TB patients have been identified and
characterized, albeit no single antigen appears to be ideal yet for
the development of immunodiagnosis tests [8,10,11]. Therefore,
identification of appropriate Mtb antigens suitable for immunodi-
agnosis, that offers ease of detection, high specificity and sensitivity
allowing distinguishing patients with active disease from BCG-
vaccinated and latently infected individuals are highly desirable.
One of the potential strategies in developing new TB diagnostic
assays consists in the identification of new candidate antigens,
such as lipolytic enzymes, that rely on particular aspects of the
physiology of the tubercle bacilli.
During infection, Mtb accumulates intracellular lipid-loaded
inclusion bodies [12] whose lipids probably originate from the host
cell membrane degradation [13,14,15,16]. There is now strong
evidence supporting that fatty acids also represent a source of
carbon during dormancy [17,18,19]. Mtb stores fatty acids in the
form of triacylglycerol (TAG) as it enters in the non-replicating
persistence stage. Moreover, granulomas have been found to
contain foamy macrophages that are cells bearing large amounts of
neutral lipids surrounded by phospholipids in their cytoplasm.
These lipid bodies are induced by the internalisation of bacteria and
therefore providing a carbon source for the pathogen [20]. Overall,
these findings support the view that enzymes involved in lipid
degradation may fulfill important physiological functions and may
participate in the extraordinary capacity of survival of Mtb within
the infected host. Acquisition of host lipids by Mtb is likely to
be performed by lipolytic enzymes, such lipases and phos-
pholipases, including the cutinase family enzymes [14]. To date,
except Rv0183 identified as a monoglyceride lipase [21], lipases
belong to the Lip family which includes 24 lipid/ester hydrolases
called LipC to LipZ based on their presence of the consensus
sequence GXSXG characteristic of members of the a/b hydrolase
fold family. Due to its location in the cell wall, Rv0183 has been
proposed to participate in bacterial cell interactions [22]. Other
lipases have been classified as cutinases, which are serine esterases
active on a large panel of substrates such as cutin from plants [23],
TAGs [24] and phospholipids [25]. Mtb possesses at least seven
genes related to the cutinase family. Among this family, two
enzymes are secreted, Rv1984c which preferentially hydrolyses
medium-chain carboxylic esters and monoacylglycerols and
Rv3452 which behaves like a phospholipase A2 and is able to
induce macrophage lysis [16]. From their central role in
mycobacterial metabolism and their participation as interacting
players between bacilli and host cells, it may be inferred that specific
antibodies against lipolytic enzymes may be induced at different
stages of the infection process, therefore providingpotentialrelevant
diagnosis markers of TB. This hypothesis has recently been
examined with respect to LipY (Rv3097c, PE30), a lipase that is a
member of the PE family. LipY expresses TAG hydrolase activity
[26]. It appears strongly associated to the mycobacterial cell surface
[27] and its accessibility to the host immune system was supported
by the induction of a strong specific humoral response in TB
patients living in an endemic area [27]. This prompted us to extend
these initial observations and to investigate whether other Mtb
lipolytic enzymes also induce specific immune responses in patients
with either active or latent infections.
Herein, we have examined the humoral response against four
distinct Mtb lipolytic enzymes in different patient groups. These
antigens including LipY, the monoacylglycerol lipase Rv0183 as
well as two cutinase-like proteins (Rv1984c and Rv3452) were
chosen as members of different lipolytic enzyme families charac-
terized by distinct expression profiles and substrate specificities.
Results
Expression and purification of M. tuberculosis lipolytic
enzymes
The main proteomic and enzymatic characteristics of the
Rv0183, Rv1984c, Rv3097c and Rv3452 are depicted in Table 1.
These data indicate that all four enzymes can be distinguished
with respect to the presence of particular protein domains,
enzymatic activity, localization and genetic distribution. Briefly,
whereas Rv0183 could be excreted from the cell wall [21],
Rv1984c and Rv3452 have been reported to be secreted [16] and
Rv3097c (LipY) has been shown to be strongly associated to the
mycobacterial cell wall and surface-exposed [27]. This latter is also
the only one that possesses a N-terminal PE domain which has
been suggested to participate in the regulation of the catalytic
activity of the lipase [27]. In addition, distribution of lipY is only
restricted to some mycobacterial species, including members of the
Mtb complex as well as M. marinum, in which the PE domain is
substituted by a PPE domain [27]. Rv0183 is found in most
mycobacterial species [21]. Cutinases have been found in
phytopathogenic bacteria and in various environmental mycobac-
terial species, such as Mycobacterium vanbaalenii and Mycobacterium sp.





(AA) M (kDa) pI Secreted RD region Enzymatic activity References
Rv0183 - + 279 30.3 6.17 + 2 MAG hydrolase [21,22]
Rv1984c Cfp21/Culp1 + 217 21.8 5.88 + RD2 Lipase [16,54]
Rv3097c LipY/PE30 2 437 45.0 4.26 ND 2 Lipase [26,27]
Rv3452 Cut4/Culp4 + 226 23.1 9.33 + 2 Phospholipase [16,54]
ND, not determined; M, molecular weight, pI, isoelectric point; RD, region of differentiation; MAG, monoacylglycerol.
doi:10.1371/journal.pone.0025078.t001
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region of differentiation 2 (RD2), which is deleted from BCG
substrains derived from the original BCG Pasteur strain during
year 1926-1931 [28]. Therefore, RD2 constitutes a potential
source of specific antigens for TB immunodiagnosis [29]. Rv0183
and LipY have been shown to exhibit monoacylglycerol (MAG)
and triacylglycerol (TAG) hydrolytic activities, respectively,
whereas the two cutinase-like enzymes have been demonstrated
to hydrolyse either medium-chain carboxylic esters and MAGs (for
Cfp21) or phospholipids (for Rv3452).
All four enzymes were cloned and expressed as N-terminally His
tagged recombinant proteins, either in E. coli for Rv0183, Rv1984c
and Rv3452 or in M. smegmatis for LipY. Following overexpression,
Ni
2+-charged immobilized metal affinity chromatography was
utilized to purify the proteins, subsequently analyzed by SDS-
PAGE (Figure S1). Because LipY was found to be strongly
associated to the mycobacterial cell wall, a method using N-
lauroyl-sarcosine was developed to extract and purify this protein.
This allowed us to obtain high yields of active LipY produced in a
mycobacterial membrane environment and at high purity levels
(Figure S1).
IgG antibody response against LipY, Rv0183, Rv1984c
and Rv3452 in active TB patients
All four proteins have been demonstrated to be either surface-
exposed or secreted into the culture filtrate of Mtb, leading to the
hypothesis that they are accessible to the immune system of the
infected host [27]. However, little is known regarding their
immunogenic properties. We, therefore, evaluated their role as
antigens in clinical settings. Four individual indirect ELISA were
optimized and used to analyse sera from distinct patient groups.
First, the IgG response against the different selected antigens was
determined in samples from polish (n=62) and french (n=43)
patients with active TB or in subjects without active TB.
Characteristics of the included subjects are provided in Table 2.
The receiver operating characteristic (ROC) curves, which
describe the relationship between the sensitivity and specificity at
any cut-off values, are depicted in Figure 1A. The ratio mean and
the area under the curve (AUC) of each antibody response are
provided in Figure 1B. The AUC for LipY, Rv0183, Rv1984c and
Rv3452 were 0.89 (0.84–0.94), 0.93 (0.89–0.97), 0.95 (0.91–0.99)
and 0.98 (0.97–1.00), respectively. Based on the AUC values, cut-
off levels for each antigen were set to generate the optimal
combination of specificity (96%) and sensitivity. AUC values were
found to be significantly different between Rv3452 and LipY
(p,0.0001), Rv3452 and Rv0183 (p,0.01) and Rv1984c and
LipY (P,0.05).
The humoral IgG response to each antigen in active TB patients
as opposed to BCG
+ healthy controls is shown in Figure 2. The
specificity to all four antigens was determined using three different
populations: french BCG-vaccinated blood donor (BCG
+ BD,
n=50), french hospitalized patients which were BCG-vaccinated,
had no declared TB neither latent TB based on a negative IFN-a ˜
release assay (IGRA) (TB
-HP; n=50) and french latent TB
infection patients (LTBI; n=49). As shown in Table 3, a specificity
of 96% for all four antigens was achieved in the BCG
+ blood
donors. Very high specificity values were also obtained against the
TB
-HP population, ranging from 94% (for Rv3452) to 100% (for
LipY). For the latently infected population, the specificity varied
between 87.8% (for Rv1984c) to 95.9% (for LipY).
As shown in Table 3, the sensitivity varied from 73.4% to
90.5%, Rv3452 being the more potent antigen when assessing the
total TB population comprising both the polish and french
patients. However, when both populations were analyzed
separately, one could clearly distinguish an important sensitivity
difference. Accordingly, the sensitivity of all four antigens was
significantly higher in the polish TB population, ranging from
91.9% (82.2%–97.3%) for LipY to 100% (94.6%–100%) for
Rv0183 compared to the french TB population, ranging from
46.5% (31.2%–62.3%) for LipY to 81.4% (66.6%–91.6%) for
Rv3452 (p,0.05).
Overall these results clearly highlight the potential of lipolytic
enzymes and the excellent performances of Rv3452 in the
diagnosis of active TB.
Serological responses in latent TB patients
T-cell responses, even for the most immunodominant antigens,
including ESAT-6 and CFP-10, do not allow to discriminate
between active TB infection and latent infection [30]. Likewise,
ESAT-6 and CFP-10 antibodies are present in active TB patients
but also in latent infection individuals, particularly in areas with
high levels exposure to Mtb [31]. Several recent studies also
highlight the insufficient specificity of serodiagnostic tests designed
to detect active TB and used in TB epidemic regions [32,33].
Therefore, we evaluated the specific IgG responses against all four
antigens in sera from latent TB infected individuals proved by a
positive result with IGRA. Positive rates for LipY, Rv0183,
Rv1984c and Rv3452 were 4.1%, 10.2%, 12.2% and 6.1%, thus
highlighting the very low response elicited against the four antigens
tested in latently infected patients.
Therefore, the difference between active TB and latent TB
groups in humoral responses to all four lipolytic enzymes suggests
that these antigens could serve to successfully discriminate active
from latent TB infections.
Table 2. Clinical characteristics of the populations.
Number of patients
Serum origin Tuberculosis type Total number of sera Smear positive Smear negative Culture positive ELISPOT positive
Total TB patients 105 82 23 N.A.
Poland Pulmonary TB 62 56 6 N.A.
Extra-pulmonary TB 0 0 0 N.A.
France Pulmonary TB 37 24* 13 N.A.
Extra-pulmonary TB 6 2 4 N.A.
Total LTBI patients 49 0 0 49
*includes 2 HIV
+ patients; TB, tuberculosis patients; LTBI, latent tuberculosis infection; N.A., non available.
doi:10.1371/journal.pone.0025078.t002
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the microbiological status
Positive IgG sera were next compared with the bacteriological
status determined by microscopy and culture (Table 4). The data
indicate the presence of a different response according to the result
of microscopic examination for the presence of acid-fast bacilli
(AFB). For instance, anti-LipY antibodies were found in 82.9% in
smear-positive patients and in 64.7% in smear-negative culture-
positive patients. The proportion of patients suffering from active
TB without AFB detected by microscopic examination was found
to be more pronounced in the french than in the polish
population. In this analysis, Rv0183 appeared as the least potent
marker as specific antibodies were detected in only in 52.2% of
smear-negative patients. In contrast, regarding Rv3452, antibodies
were detected in 92.7% of the smear-positive patients and 87.0%
in smear-negative patients (Table 4).
Discussion
Antibody responses are typically investigated in infectious
diseases where antibody production strongly affects pathogenesis
and the outcome of the infection. Antibodies are also produced in
infections caused by intracellular pathogens, including TB, where
the protective immunity is primarily elicited by the T-cell response
[34]. Although approximately 90% of TB patients produce
antibodies to Mtb proteins [35], much remains to be learnt with
respect to the correlation between antibody production, antibody
specificity and disease progression. During the last few years, an
important number of studies have been dedicated on circulating
antibodies in TB patients with the goal of evaluating them as
biomarkers of active disease. However, despite of intense research
in this particular field, the World Health Organization has, for the
first time, delivered negative recommendations against the use of
the current commercial TB immunoassays based on antibodies
detection because they may be doing more harm than good in
high-burden countries. Low sensitivity means increased false
negative results, which increase mortality and ongoing transmis-
sion of TB. Low specificity means more false positive results and
then, patients might be given 6 months of potentially toxic
treatment [36]. However, in the same time the WHO has claimed
that biomarker discovery remains a major challenge to the
establishment of an efficient serodiagnostic test for the tuber-
culosis (http://www.stoptb.org/assets/documents/global/plan/
TB_GlobalPlanToStopTB2011-2015.pdf).
In this context, we reasoned that efficient biomarkers for the
diagnosis of TB should derive from novel concepts with respect to
the biology/physiology of Mtb. In our recent studies, several
lipolytic enzymes of Mtb were characterized both biochemically
and enzymatically [16,21,22,27], allowing us to propose that these
enzymes, or at least some of them, are very likely to participate in
lipid metabolism during dormancy and/or during reactivation
[14]. This view is supported by a recent study conducted by Low
et al. demonstrating extensive accumulation and degradation of
TAGs in the bacilli during entry into and exit from hypoxia-
induced dormancy, respectively [37]. Moreover, these processes
are accompanied by dynamic appearance and disappearance of
intracellular TAG lipid particles [19]. Importantly, reduction of
TAG levels coincides with an increase in cellular TAG lipase
activity in regrowing bacilli, leading to the conclusion that TAG
utilization is essential for the regrowth of mycobacteria during
their exit from the non-replicating state [37]. Therefore, one may
hypothesize that lipolytic enzymes such as LipY, which is not
expressed under normal growth conditions [27], are mainly
induced and expressed under reactivation conditions, and hence,
may represent useful biomarkers to detect reactivated forms of TB.
Herein, we provide for the first time evidence that proteins
Rv0183 and Rv3452 induce robust humoral responses in TB
patients. Regarding Rv1984c, Wang et al. reported an anti-
Rv1984c IgG response in pulmonary TB patients with a sensitivity
of 46.2% and a specificity of 100% [38]. In our study, a higher
sensitivity level was achieved (81.9%). This difference may be
attributed to the purity rate of the recombinant protein, the
Figure 1. ROC analysis of the antibody response against four M. tuberculosis lipolytic enzymes. (A) Comparison of the ROC curves for IgG
detection specific to LipY (blue), Rv0183 (pink), Rv1984c (green) and Rv3452 (red). The grey line represents the no-discrimination line from the left
bottom to the top right corners. (B) Ratio mean, standard deviation (SD) and area under the ROC curve (AUC) derived from (A). The p value for active
TB patients versus healthy controls (BCG
+ BD) is ,0.0001. BCG
+ BD, BCG vaccinated blood donors; n, number of sera; CI, confidence interval; SD,
standard deviation.
doi:10.1371/journal.pone.0025078.g001
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Subjects group (n) LipY Rv0183 Rv1984c Rv3452
Specificity (%) (95% CI)
Total control (149) 97.3 (93.3 to 99.3) 93.3 (88.0 to 96.7) 94.0 (88.8 to 97.2) 94.6 (89.7 to 97.7)
French BCG
+ BD (50) 96.0 (86.3 to 99.5) 96.0 (86.3 to 99.5) 96.0 (86.3 to 99.5) 96.0 (86.3 to 99.5)
French TB
- HP (50) 100.0 (92.9 to 100.0) 94.0 (83.5 to 98.7) 98.0 (89.3 to 99.9) 94.0 (83.5 to 98.7)
French LTBI (49) 95.9 (86.0 to 99.5) 89.8 (77.7 to 96.6) 87.8 (75.2 to 95.4) 93.9 (83.1 to 98.7)
Sensitivity (%) (95% CI)
Total TB (105) 73.4 (63.8 to 81.5) 81.0 (72.9 to 88.3) 81.9 (73.2 to 88.7) 90.5 (83.2 to 95.3)
Polish TB (62) 91.9 (82.2 to 97.3) 100.0 (94.6 to 100.0) 98.4 (91.7 to 100.0) 96.8 (88.8 to 99.6)
French TB (43) 46.5 (31.2 to 62.3) 53.5 (37.7 to 68.8) 58.1 (42.1 to 73.0) 81.4 (66.6 to 91.6)
n: number of subjects; BCG
+ BD: BCG vaccinated blood donors, TB
-HP: non-tuberculosis hospitalized patients, TB: tuberculosis patients, LTBI: latent tuberculosis
infection.
doi:10.1371/journal.pone.0025078.t003
Figure 2. Comparison of the antibody IgG response to recombinant lipolytic enzymes in TB patients and healthy individuals.
(A) LipY, (B) Rv0183, (C) Rv1984c and (D) Rv3452. Horizontal lines indicate the mean value, whereas dotted lines indicate the cut-off values, derived
from the ROC curves. BCG
+ BD, BCG vaccinated blood donors (n=50), TB, active TB patients (n=105).
doi:10.1371/journal.pone.0025078.g002
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studied.
With respect to LipY, these data are in agreement with those of
Mishra et al. [27] reporting a humoral response against LipY in
patients suffering from pulmonary TB or extrapulmonary TB.
However, among the four antigens, LipY appears like the least
attractive, albeit it was expressed and purified from M. smegmatis,
which allows more accurate processing of gene products, including
folding and eventual post-traductional modifications, than expres-
sion in E. coli [39,40]. In contrast to Rv1984c and Rv3452, which
have proposed be secreted by Mtb, LipY has been shown to be
strongly associated to the mycobacterial cell wall and surface-
exposed. These differences in localization may influence the
intensity of the immune response, although this remains to be
further investigated. Among the studied antigens, Rv3452 exhibits
the best performances to diagnose active TB. Several studies have
demonstrated that the detection of antibodies directed against
multiple antigens provides an improvement in sensitivity com-
pared to the use of a single antigen [41,42]. However, as shown in
Table S1, the sensitivity in total TB patients was not significantly
enhanced (93.3% when individually combined together with each
single antigen versus 90.5% when assayed alone (Table 3)).
Moreover, this little gain in sensitivity was counter-balanced by a
decrease in specificity value (85.2% versus 94.6% when assayed
alone).
Poland and France are low TB endemic areas. The prevalence
of the TB in Poland is of 32 cases per 100,000 inhabitants, whereas
in France, the prevalence is of 7.3 cases to 100 000 inhabitants [2].
However, our data highlight an important difference with respect
to the IgG response against all fours antigens between polish and
french TB patients, that is reflected by a significant difference in
the sensitivity between the two populations (91.9% [82.2%–
97.3%] versus 46.5% [31.2%–62.3%] for LipY or 100.0%
[94.6%–100.0%] versus 53.5% [37.7%–68.8%] for Rv0183). This
discrepancy may be linked to the microbiological status of the
patients analyzed. Previous studies have shown that detection of
antibodies against the 38-kDa protein or lipoarabinomannan has
high sensitivity and specificity in active TB patients, but is poor in
detecting a reponse in smear-negative TB patients [43,44]. Indeed,
in our study, only 9.7% of the patients in the polish population is
smear-negative (6 out of 62), compared to 39.5% (17 out of 43) in
the french population (Table 2). Alternatively, the difference in
sensitivity may be influenced by disease progression and by the
extent of cavitation which affects the antibody response, as
suggested in previous studies [45,46,47]. Indeed, the presence or
absence of cavitary lesions has a significant, reproducible effect on
the profile of antigens that are recognized by the antibodies [46]. It
had been proposed that the presence of antibodies to some
antigens in cavitary TB patients suggests that in vivo either these
antigens are expressed primarily during extracellular replication of
the bacilli in liquified caseous material or that these antigens are
accessible to the immune system only during this particular stage
of the disease. It remains, however, to be established whether the
observed differences between french and polish populations
correlate with differences in their radiological status even when
they are bacteriologically similar.
Another possible explanation of the difference in sensitivity
between french and polish populations may also rely on exposition
to various environmental mycobacteria, as this may also impact in
generating cross-reactive antibodies, especially if antigens are not
Mtb-specific. However, further studies are required to evaluate the
eventual impact/contribution of infection with environmental
mycobacteria on the accuracy of these antigens.
In addition, among the french patients, 6 suffered from extra-
pulmonary TB cases and two were HIV co-infected, all these cases
being absent from the polish population. Only two extra-
pulmonary TB cases contained IgG against LipY, Rv0183 and
Rv1984c. In contrast, 5 out of 6 of these patients presented an
anti-Rv3452 IgG reponse (data not shown). Therefore, it appears
very likely that the lower sensitivity values obtained with the
different markers in the french population is directly associated to
the occurrence of a highly heterogenous population with respect to
the bacteriological and clinical status. It is, however, noteworthy
that some of the markers studied, particularly Rv3452, exhibited
very good serodiagnostic properties in both population (93.9% to
96% of specificity in the control populations, 96.8% of sensitivity
in the polish population and 81.4% in the french population), thus
suggesting that this marker is of high value for future diagnostic
Table 4. Number of IgG positive response of TB serum according to bacteriological status.
Number of TB sera (% positive sera)
Antigen Serum origin (n=105) Smear positive (n=82) Smear negative Culture positive (n=23)
LipY Poland 53 (94.6) 6 (100.0)
France 15 (57.7) 5 (29.4)
Total 68 (82.9) 11 (64.7)
Rv0183 Poland 56 (100.0) 6 (100.0)
France 17 (65.4) 6 (35.3)
Total 73 (89.0) 12 (52.2)
Rv1984c Poland 55 (98.2) 6 (100.0)
France 18 (69.2) 7 (41.2)
Total 73 (89.0) 13 (76.5)
Rv3452 Poland 54 (96.4) 6 (100.0)
France 22 (84.6) 14 (82.4)
Total 76 (92.7) 20 (87.0)
n, number of sera; N.A., non availaible; n total of polish sera = 62; n total of french sera = 43; n of smear positive of polish sera = 56; n of smear positive in french sera
= 26; n of smear negative and culture positive of polish sera = 6; n of smear negative and culture positive of french sera = 17.
doi:10.1371/journal.pone.0025078.t004
Lipolytic Enzymes as New TB Diagnosis Markers
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e25078developments. This is also strengthened by the fact that Rv3452
IgG antibodies were detected in extra-pulmonary TB cases and in
both HIV/TB co-infected patients (data not shown).
We have also investigated whether the active TB patients were
able to mount specific IgM antibody responses against the four
antigens. In contrast to IgG, very few patients exhibited specific
IgM responses to the various antigens (Table S2). For instance,
only 9.5% patients displayed IgM seropositivity to Rv3452
whereas 90.5% were IgG-positive. Comparing both IgG and
IgM responses indicated that some patients displayed specific IgM,
but not IgG, antibodies. Indeed, two patients developed anti-LipY
IgM antibodies but not anti-LipY IgG antibodies, and sera from
four patients contained anti-Rv0183 IgM but not IgG antibodies
(Table S2). IgM antibodies are usually the first to appear in
response to any antigen and are expected to be produced in larger
quantities following primary TB infection and to decline in more
advanced phases. Several authors suggested that IgM are
produced mainly during the early phase of primary TB infection
[48]. One may therefore hypothesize that the IgM-positive
patients were diagnosed at an early stage of the infection process.
Identification of new targets is also required for the detection of
LTBI. In our study, no discrimination was observed between
control individuals and latent TB infected people (p.0.05). IGRA
represent the methods generally used to diagnose LTBI. For these
purposes, several antigens have been successfully used, like ESAT-
6 and CFP-10 in QuantiFERONH and T-SPOT-TBH tests.
Interestingly, Rv1984c has also previously been shown to induce
IFN-a ˜ release in the Guinea pigs, mice and TB patients [49,50,51].
Therefore, evaluating the release of IFN-a ˜ after stimulation of T
cells with LipY, Rv0183 or Rv3452 may represent an alternative
to IGRA option, particularly if it permits to distinguish latent from
active TB.
In conclusion, to replace the gold standard culture, an
immunoassays should possess sensitivities of over 80% and test
specificities of over 95% according to the recommendations of the
WHO [2]. Using the Mtb lipolytic enzymes tested in the present
study these criteria were achieved. Further studies, including field
trials, are now required to evaluate the potential and usefulness of
Rv3452 for TB diagnosis in smear-negative and HIV-infected
persons in countries highly afflicted by HIV and TB.
Materials and Methods
Collection of blood serum
Fifty sera of healthy blood donors from France vaccinated with
BCG (negative for HIV) and 50 hospitalized non-TB subjects
vaccinated with BCG and negative for TB as detected by IGRA
tests (T-SPOT-TB
TM, Oxford Immunotec, UK) were analyzed in
this study. In addition, two groups of patients with active TB were
included. In the first group, sera from 62 patients suffering from
active pulmonary TB were collected in Poland. As detailed in
Table 2, among these patients 56 patients were positive by smear
microscopy. The second group comprises 43 french patients with
active TB (37 patients with pulmonary TB and 6 extrapulmonary
TB, with 26 smear-positive patients, including 2 HIV-positive
patients. In another group of 49 subjects, latent TB infection was
diagnosed using the T-SPOT-TB
TM (Table 2).
Ethics statement
The sera of healthy blood donors were supplied by the Center of
Blood Transfusion (Centre de transfusion sanguine de Lille,
France). Their use is in accordance with all relevant national
and European Union regulations. Patients were included after
having given written consent (AFSSAPS nu 2010-A00422-37), in
compliance with the Helsinki declaration and after approval of the
local ethics committee (Comite ´ Consultatif de Protection des
Personnes pour la Recherche Biome ´dicale de Nimes, France). All
samples were treated anonymously. Antibodies were produced in
New-Zealand rabbits using recombinant antigen following ap-
proval by Ms L. De-Coninck, the person duly entlitled at Bio-Rad
to conduct animal experimentations in the respect of ethic rules,
agreement Nu 59-580140, delivered by the Prefecture du Nord,
France. There was no specific ethic comity but all experimentions
were done following standard protocols, examined and approved
by Ms L. De-Coninck, who also warrants that all experimentations
were performed with respect the required ethical rules. Articles
R214-87 to R214-122 and article R215-10 of the French Rural
Code in conjunction with the French administrative order dated
19 April 1988 establish eligibility conditions for authorization to
conduct experiments on animals. Permission is given to a person to
review the ethical compliance of protocol conducted in animals
according to the recommendations of the French and European
Community guidelines for laboratory handling, and to allow
research to be carried out when these criteria are met.
Bacterial strains
Escherichia coli Rosetta pLysS was used for the expression of
recombinant Rv0183 and Rv1984c, whereas C41(DE3) was used
to overproduce Rv3452 [16,21]. LipY was expressed from
recombinant M. smegmatis mc
2155, as reported earlier [27].
M. tuberculosis lipolytic enzymes expression constructs
The Rv0183, Rv1984c, Rv3452 genes lacking their predicted
signal peptide and Rv3097c were amplified from cosmids
MTCI28.23, MTCY39, MTCY13E12 and BAC 48, respectively
(obtained from the Pasteur Institute). Rv0183, Rv1984c and Rv3452
were cloned into pDest14 (Invitrogen) using the gateway tech-
nology, giving rise to pDest14-His-Rv0183, pDest14-His-Rv1984c
and pDest14-His-Rv3452, respectively [16,21]. These constructs
allow the expression of N-terminal His-tagged fusion proteins
containing a TEV protease recognition site. Rv3097c was cloned
into the acetamide-inducible vector pSD26 [52], as described
previously [27].
Expression and purification of Rv0183, Rv1984c and
Rv3452
Recombinant proteins were expressed and purified as described
previously [16,21]. Briefly, E. coli strains carrying pDest14-His-
Rv0183, pDest14-His-Rv1984c or pDest14-His-Rv3452 were grown
overnight in LB medium at 37uC and then diluted in Terrific
Broth. Protein expression was induced with 1 mM isopropyl b-D-
thiogalactoside (IPTG) and the temperature decreased to 25uC for
another 16 hrs. Bacteria were lyzed in 50 mM Tris/HCl pH 8.0,
150 mM NaCl, 1 mM EDTA, 0.1% Triton X-100, 0.25 mg/ml
lysozyme supplemented with 10 mg/ml DNAseI and 20 mM
MgSO4. For purification of Rv0183, the supernatant was
separated from the cell debris and loaded onto a Ni
2+-Agarose
column After washing with buffer A (10 mM Tris/HCl pH 8.5,
150 mM NaCl) containing 10 mM imidazole, the protein was
eluted with buffer A supplemented with 500 mM Imidazole.
Fractions were pooled and further purified by size exclusion
chromatograph (Superdex 200) in buffer A.
Recombinant Rv1984c and Rv3452 were expressed only in an
insoluble form [16]. After washing inclusion bodies were
resuspended overnight at 4uC in 50 ml of buffer A containing 8
M urea. After centrifugation at 17,000 g, solubilized proteins were
loaded onto a Ni
2+-NTA resin equilibrated with buffer A
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supplemented with 250 mM imidazole. Fractions were pooled and
incubated with 10 mM DTT for 1 hr at 4uC. Proteins were
diluted 20 times in the appropriate buffer selected from the
refolding plates [53] and left to refold overnight at 4uC under
gentle agitation. Soluble proteins were concentrated and further
purified by size-exclusion chromatography column (Superdex 200)
equilibrated with the appropriate buffer. Pure rRv1984c and
rRv3452 were obtained in 10 mM Tris/HCl (pH 8) containing
300 mM NaCl and 50 mM 2-(N-cyclohexylamino)ethane sulfonic
acid (pH 9) refolding buffers, respectively.
For all three proteins, N-terminal His tags were removed by
TEV digestion and purified by exclusion from a Ni
2+-NTA
agarose beads. Protein concentration was calculated from the
OD280nm using the extinction molar coefficients 0.858, 0.78,
0.651 M
21.cm
21 for Rv0183, Rv1984 and Rv3452, respectively,
and stored at 280uC until further use.
Expression and purification of LipY
Expression of recombinant LipY was performed using M.
smegmatis mc
2155 strain as previously reported [27] with some
modifications. Briefly, M. smegmatis carrying pSD26_LipY was
used to inoculate 4 ml of 7H9 medium containing 50 mg/ml
hygromycin B and used to inoculate 400 ml of culture medium for
large-scale production. Cells were grown at 37uC with shaking
(220 rpm) until an OD600nm value of 3 was reached. Expression of
recombinant proteins was induced for by adding 0.2% acetamide
for another 16 hrs. Bacteria were harvested and resuspended in
ice-cold buffer consisting of 10 mM Tris/HCl buffer (pH 8.0)
containing 150 mM NaCl and 1% N-lauroyl-sarcosine (sarcosyl)
and subsequently broken. The supernatant was recovered whereas
the pellet was resuspended again and sonicated thrice during 30 s
with 30 s breaks between each cycle and stirred overnight at 4uC.
Both supernatants were then pooled and loaded onto a Ni
2+-NTA
resin equilibrated with 10 mM Tris-HCl buffer (pH 8.0) contain-
ing 150 mM NaCl and 1% sarcosyl. The column was subse-
quently washed with buffer without detergent prior elution with
increasing concentrations of imidazole. Fractions containing pure
LipY were pooled, dialysed overnight against 10 mM Tris-HCl
buffer (pH 8.0) containing 150 mM NaCl and concentrated by
ultrafiltration to a final concentration of 0.5 mg/ml.
Production and purification of polyclonal antibodies
Anti-LipY antibodies were produced in two rabbits (New-
Zealand) using recombinant LipY as antigen. One rabbit was
injected subcutaneously and one rabbit was injected intramuscu-
larly. Each rabbit was injected four times every two weeks with
250 mg of antigen mixed with an equal volume of incomplete
Freund’s adjuvant (Sigma). Polyclonal LipY antibodies were
purified by affinity chromatography on Protein A agarose
(Streamline rProtein A, Ge Healthcare). Specificity of the
antibodies response was assessed by an ELISA. A similar protocol
was carried out with Rv0183, Rv1984c and Rv3452. All
experiments were performed in accordance with French and
European Community guidelines for laboratory animal handling.
Preparation of HRP-conjugates for ELISA
To prepare the HRP (horseradish peroxydase)-conjugates
derived from each polyclonal antibody, Ab/HRP (Roche) labeling
ratios of 1/4 (mol/mol) were used. HRP was oxidized with 0.1 M
sodium periodate. Oxidation was blocked with 0.85 M ethylene
glycol and oxidized HRP was purified on a PD-10 desalting
column (GE Healthcare) with 0.1 M carbonate buffer. Fraction
were monitored by measuring the OD280nm, pooled and used for
the binding with antibodies. Coupling was performed in 1 M
carbonate buffer overnight in the darkness and then stopped with
2.5% sodium borohydride for 15 min at room temperature in the
darkness. The conjugate was then dialyzed against 0.01 M PBS
overnight at 4uC. Protein concentration was determined using the
BCA kit (Pierce) according to the manufacturer’s instructions.
Antibody detection by ELISA
For the detection of specific IgG antibodies, 100 ml of Individual
recombinant proteins (1 mg/ml for Rv0183 and 3 mg/ml for
Rv3452, 4 mg/ml for LipY and Rv1984c), were used to coat the
wells in 96-well microtiter plates (Nunc) overnight. Then, the wells
were blocked twice with 300 ml of blocking buffer (5% saccharose,
0.1% bovine serum albumin (BSA) in PBS), 100 ml of serum
(diluted 1:100) were added and incubated for 1h at 37uC. After
washing, the bound antibodies were detected by 100 ml of HRP-
conjugated mouse anti-human IgG (20 ng/ml) (Bio-Rad) incubat-
ed for 1 h at 37uC. After a last washing step, 200 ml of enzymatic
substrate (tetramethylbenzidine [TMB] and peroxide hydrogen)
was added and incubated at room temperature before stopping the
reaction by 100 ml of 1 N sulfuric acid. Intensity of the reaction
was assessed by measuring the OD450nm in an ELISA plate reader
(PR 3100, Bio-Rad).
For the detection of specific IgM antibodies, 100 ml of goat
anti-IgM antibodies (2 mg/ml) (Bio-Rad) were coated in 96-well
microtiter plates overnight at 4uC. After washing and incubation
in blocking buffer, 100 ml of each serum (diluted 1:100) were
added and incubated for 1 h at 37uC. The various antigens
(0.1 mg/ml for LipY and Rv1984c, 1 mg/ml for Rv0183 and
Rv3452) were mixed with their corresponding rabbit IgG-HRP
conjugates (1 mg/ml) prior to the addition of 100 ml of the mix in
the wells. After incubation for 1 h at 37uC, plates were washed and
detection was performed by adding 200 ml of TMB and peroxide
hydrogen and stopped by adding 100 ml of sulfuric acid. The
OD450nm was measured using an ELISA plate.
Data management and statistical analysis
All data were entered into a Microsoft Office Excel file. The
ratio value corresponding to the sample OD450nm/buffer OD450nm
was determined for each sample. The mean and standard
deviation of the ratio of individual groups for antibody/antigen
responses to each marker were calculated. The receiver operating
characteristic (ROC) curves of the ratio values for antibody
responses to each marker were plotted using Analyse-it software
and the area under the curves and 95% confidence intervals (95%
CI) for responses to each antigen were calculated. Individuals were
scored as positive for the specific antibody response when their
ratio value was greater than or equal to the cut-off value. Results of




Figure S1 SDS PAGE analysis of the purified lipolytic
enzymes used in this study. MW: Molecular weights are
presented in the left margin. Rv0183 and LipY were loaded onto a
12% polyacrylamide gel while Rv1984c and R3452 were loaded
onto a 15% polyacrylamide gel. Rv0183 (5 mg), LipY (4 mg),
Rv1984c (5 mg) and Rv3452 (10 mg).
(PDF)
Table S1 Relative specificity and sensitivity of the
IgG detection against combination of M. tuberculosis
antigens.
(PDF)
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